My second question deals with the issue of my understanding that the number of companies and NGOs....
There are two cases. One is a public case and one is confidential, in terms of take-up of the system. On page 10, you have a statement:
• The Minister of Health announced an early review of CAMR....
• On November 24, 2006, the Government released a consultation paper....
• During the subsequent 60-day consultation period, Industry Canada and Health Canada received approximately 30 submissions from interested parties....
Clearly there's interest in the legislation, in the issue. There's a system in place. I'm not sure whether the system is what's wrong or whether it's the take-up in the system. Mr. Byrne certainly raised some valid questions in terms of whether you need CIDA to take some leadership.
In terms of the system, we don't have a lot of cases to go on in terms of analyzing whether it's working or not. The one case that is public and that we can talk about is the case with respect to Apotex and a drug that I believe is called APO-TriAvir. According to Apotex's submissions to the government's statutory review of this legislation, this has not happened because of the complexity of the process, so nothing has moved since.
Just using this one case, because it's the one case we can talk about, can you explain to the committee the development of that process and why it has not moved forward from a regulatory point of view?